US Medical Morphine Market

ID: MRFR/MED/54387-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
US Medical Morphine Market Research Report By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), By Application (Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, Others) and By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Home Care) -Forecast to 2035
US Medical Morphine Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.5%
2024 Market Size$ 6.5 Billion
2025 Market Size$ 6.92 Billion
2035 Market Size$ 13 Billion
Key Players
Purdue Pharma
Mallinckrodt Pharmaceuticals
Teva Pharmaceutical Industries
Mundipharma
Hikma Pharmaceuticals
Amgen
Opportunities
  • Rising Pain Management Needs
  • Increased Focus on Palliative Care
  • Growing Awareness of Opioid Therapy
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Route of Administration (USD Billion)
      1. 4.1.1 Oral
      2. 4.1.2 Injectables
    2. 4.2 Chemicals and Materials, BY Distribution Channel (USD Billion)
      1. 4.2.1 Hospital Pharmacy
      2. 4.2.2 Online Pharmacy
      3. 4.2.3 Retail Pharmacy
      4. 4.2.4 Others
    3. 4.3 Chemicals and Materials, BY Application (USD Billion)
      1. 4.3.1 Myocardial Infarction
      2. 4.3.2 Diarrhea
      3. 4.3.3 Arthritis
      4. 4.3.4 Kidney Stones
      5. 4.3.5 Cancer
      6. 4.3.6 Others
    4. 4.4 Chemicals and Materials, BY End User (USD Billion)
      1. 4.4.1 Hospitals and Clinics
      2. 4.4.2 Ambulatory Surgical Centers
      3. 4.4.3 Home Care
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Purdue Pharma (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Mallinckrodt Pharmaceuticals (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Teva Pharmaceutical Industries (IL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Mundipharma (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Hikma Pharmaceuticals (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sandoz (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Boehringer Ingelheim (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    3. 6.3 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    14. 6.14 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    16. 6.16 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Billion)
    18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Medical Morphine Market Segmentation

US Medical Morphine Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injectables

US Medical Morphine Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

US Medical Morphine Market By Application (USD Billion, 2025-2035)

  • Myocardial Infarction
  • Diarrhea
  • Arthritis
  • Kidney Stones
  • Cancer
  • Others

US Medical Morphine Market By End User (USD Billion, 2025-2035)

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Home Care
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.